Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis

BackgroundNintedanib is a tyrosine kinase inhibitor that has recently been shown to slow disease progression in idiopathic pulmonary fibrosis in two replicate phase III clinical trials. The aim of this study was to analyse the antifibrotic effects of nintedanib in preclinical models of systemic scle...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of the rheumatic diseases 2016-05, Vol.75 (5), p.883-890
Hauptverfasser:	Huang, Jingang, Beyer, Christian, Palumbo-Zerr, Katrin, Zhang, Yun, Ramming, Andreas, Distler, Alfiya, Gelse, Kolja, Distler, Oliver, Schett, Georg, Wollin, Lutz, Distler, Jörg H W
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Biopsy Bleomycin Cell Movement - drug effects Cell Proliferation - drug effects Cells, Cultured Collagen Disease Models, Animal Disease prevention Dose-Response Relationship, Drug Drug Evaluation, Preclinical - methods Extracellular matrix FDA approval Female Fibroblasts Fibroblasts - drug effects Fibroblasts - pathology Fibroblasts - physiology Fibrosis Graft vs Host Disease - prevention & control Growth factors Humans Indoles - administration & dosage Indoles - pharmacology Indoles - therapeutic use Kinases Male Metabolism Mice, Inbred BALB C Mice, Mutant Strains Mortality Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Pulmonary fibrosis Scleroderma Scleroderma, Systemic - drug therapy Scleroderma, Systemic - pathology Skin - drug effects Skin - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!